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therapeutic use of specific antibody 
and corresponding antigen. 
Final Report 
Grant #5 RO1 CA 2595803 
Funded at the School of Applied Biology, Georgia Institute of Technology 
from July 1, 1979 to June 30, 1982. 
At the end of May 1982, Dr. Bale became seriously ill, and a six—month 
extension to this grant was requested by the Director of the School of Applied 
Biology, Dr. Thomas G. Tornabene, on June 18, 1982. 
On June 28, 1982, Dr. Bale passed away. On July 18, 1982, Dr; Thomas 
G. Tornabene requested that I, M. Angeles Contreras, be approved as Acting 
Project Director in completing the remaining testing and reporting for this 
grant for a period of six months at no cost. In your letter dated July 29, 
1982, you approved my appointment as a Principal Investigator of this grant 
through December 31, 1982. 
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Principal Investigator 	  William F. Bale 
Interim Principal Investigator 	  M. Angeles Contreras 
Title 	  Organ Specific Tumor Localizing Antibody 
Part 1. Production of an immunological probe. 
This research program was based on the premise that tumors originating 
in organs not essential to life and well-being sometimes express cell surface 
antigens unique to those organs, and that antibodies to these antigens may 
be useful in the treatment of,such tumors. 
Induction of DMBA tumors in imbred F-344 rats. 
Tumors were induced in imbred F-344 rats by stomach administration of 
DMBA. It took 2-8 months for the rats to develop the tumors. A mammary tumor 
was surgically removed from each rat as tumors developed, and a tumor line 
from each rat was established by subcutaneous implant in the same strain of 
rats. The first tumor line is now in the 37th generation. A total of 8 tumor 
lines were established. One rat developed an ovarian tumor. One spontaneous 
tumor arose in an aging F-344 rat. 
Tumor antigen preparation. From each of the first generation tumor lines, 
tumor antigen was prepared Using either tumor cell membranes or by explosive 
decompression of tumor cells (Parr nitrogen bomb) followed by differential 
centrifugation in sucrose gradient. 
Antibody production. Xenogenic antibodies were produced by immunizing 
rabbits with tumor cell membranes. For immunization this antigen was combined 
with complete Freund adjuvant. 
Antibody titration. Individual serum from rabbits immunized with tumor 
cell preparation were carried out using a second antibody. This technique 
will be described under pancreas antibody titration. 
Antibody purification. In these studies, immune sera were absorbed and 
eluted onto polymerized normal rat tissues (excluding mammary tissue) in 2X 
concentrated normal rat serum. The best purification that we were able to 
obtain consisted in first absorbing and eluting the polymerized normal tissues 
3X at pH 3.2. Then we used this 3X absorbed polymer for antisera absorption. 
From this absorbed antisera y-globulin was prepared. Then this y-globulin 
was absorbed and eluted onto 3X eluted polymerized tumor membranes. The eluate 
was concentrated by negative pressure, then labeled with 1251. This 125 I-labeled 
in vitro purified preparation was in vivo screened. 
When in vitro tested, this labeled preparation showed a slightly decreased 
binding to normal rat kidney, liver and spleen, but no increase in tumor binding 
was obtained. 
When in vivo tested, this 125 I-labeled preparation showed moderate pre-
ferential localization after it was intravenously injected to tumor-bearing 
rats in all DMBA tumor lines tested. In some experiments an attempt was made 
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to reisolate the antibody which had localized in these tumors. We were able 
to elute the antibody, but the levels of radioactivity were low and no attempt 
to reinject into tumor-bearing rats was made. 
Discussion and conclusions. Our experimental results indicate that DMBA 
induced mammary tumors in rats shared common antigens on the surface of tumor 
cells that can lead to 125 1-labeled antibody localization in tumors after 
intravenous injection. We have some, although not conclusive, evidence that 
this antibody is able to localize in normal mammary tissue. We do not have 
data that excludes effects of viruses or other microorganisms that may be present 
and pass by tumor transplant from rat to rat. 
A second related conclusion is that although our data demonstrates tumor 
localizing antibody, the production of this specific antibody following our 
methods of immunization is a very small fraction of the total antibody response. 
It also seems quite clear that the procedures for specific antibody 
production and purification so far described here are too inefficient for any 
extensive studies of tumor localizing antibodies. 
Pancreas membranes antigen. Pancreas was disected out from rats under 
halothene anesthesia. Several enzyme inhibitors were used to prevent outolysis. 
After homogenization and several washes and centrifugations, the pancreas 
membranes were resuspended in 0.85% saline. Xenogenic antibodies were produced 
by immunizing rabbits with pancreas membranes in complete Freund adjuvant. 
Antibody titration. We developed a method for the titration of unlabeled 
rabbit antisera or sera fractions to rat organ or tumors. This method uses 
125 1-labeled purified goat antibody to rabbit y-globulin. A fixed amount of 
antigen was incubated with a fixed dilution of immune serum. The washed portions 
of antigen now binding to antibody were incubated with 125 1-labeled goat antibody 
containing progressible amounts of the same but unlabeled goat antibody to 
rabbit y-globulin. This method was used for titrations of immune sera to rat 
mammary tumors before purification and 125 1-labeling. 
Studies with antibodies to rat pancreas. Experiments were conducted to 
isolate pancreas-specific antibody by different elution techniques,; either 
before and after 125  I-labeling. These techniques were not successful. Most 
of the 125  I-labeled antibody bound to polymerized pancreas membranes, on elution 
turned out to be largely hydrolysed. The few trypsin inhibitors tested seemed 
relatively ineffective in preventing this hydrolysis. 
Discussion and conclusions. Our experimental results indicate that a 
very small fraction of the pancreas-specific y-globulin binds to some extent 
to pancreas tissue after intravenous injection. We do not know whether antibody 
binding takes place in the cell surface antigen. Our data indicates that this 
binding is extremely slow and perhaps the eluted antibody may be complex with 
soluble antigens and is catabolized very rapidly from the rat circulation. 
This may be one explanation for the high values of 125 1 found in the spleen. 
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Part II. Studies related to the possible therapeutic use of specific antibody  
and corresponding antigen. 
Rate of penetration of blood y-globulin into the extravascular-extracellular  
space of tumors. In vivo screened 125 1-labeled normal rabbit y-globulin was 
injected IV into rats bearing subcutaneous kidney and liver tumor implants. 
A second injection of 131 I-labeled normal rabbit y-globulin was given IV, 24 
or 48 hours later. Ten minutes after the last injection rats were sacrificed. 
The rate at which 125 1 and 131 1 accumulated in tumors was in all cases higher 
in tumor than in normal tissue. 
These results give some evidence that this physiological property of tumors 
of y-globulin sequestration in the extravascular-extracellular space of tumors 
could be of some use for possible application in boron neutron capture therapy, 
if the circulating boron covalented attached to y-globulin could be rapidly 
removed from the blood stream at the time in which boron concentration in the 
tumor is high. Two possibilities were sought. The first possibility was to 
develop an immunological technique. The second possibility was to develop 
a method for a rapid blood exchange in the rat. 
Immunological technique for removing labeled normal IGg from tumor-bearing  
rat circulation. iLs I-labeled rabbit IGg supplemented with normal rabbit serum 
was injected IV into rats bearing either subcutaneous,kidney or liver tumor 
implant. Then 24 hours later, a second injection of goat anti-rabbit y-globulin 
containing the predeterminated units of goat antibody needed to precipitate 
all rabbit y-globulin circurating in the rat blood was given. The rats were 
sacrificed 30 min. after the last injection was administered. 
Discussion and conclusions. Our results indicate that the possibilities 
of this technique are of important significance for removing almost any unwanted 
circulating chemotherapeutic agents covalently attached to y-globulin at the 
time when tumor concentrations are high. Some side effects observed in rats 
follow: on kidney implanted tumors, there was a trasient slight hemorrhage 
in the small intestine; on liver implanted tumors this hemorrhage was observed 
in colon and cecum. This hemorrhage was not present 48 hours after the second 
injection. 
The second possibility is being investigated at the present time by Miss. 
Denise J. Noonan, a Nuclear Engineer Ph.D. cancicate who was working under 
Dr. Bale's supervision in the dosimetry of boron neutron capture therapy. 
Our studies with organ tumor specific antibodies were not successful for 
any attempted therapeutic use. Therefore we did not pursue these studies further. 
Nontheless, both pancreas and mammary tissue antibodies showed a fair amount 
of avidity for these pancreas, mammary tumors and normal mammary tissues. 
Labeled antibodies remained bound to these tissues 6-8 days after being 
intravenously injected in the rat. 
With the development of more sophisticated methods it might be possible 
to continue this line of study. 
5 
Organ Specific Tumor Localizing Antibody 
1. (a) M. Angeles Contreras, William F. Bale, and Irving L. Spar. 
Iodine Monochloride (ICI) Iodination Techniques. Methods in 
Enzymology. Vol. 92 (In Press). 
2. No changes. 
3. Progress report. 
A. Objectives: 
The overall purpose of this project was to demonstrate the truth of the 
assumption that malignant tumors, arising in organs not vital to life and well-being, 
express organ specific antigens that can lead to highly preferential localization 
in such tumors after injected radioactive antibodies of the proper specificity. 
The principle goals for this year were to continue our efforts on the 
production of antibodies localizing in rat mammary tumors. 
B. Studies conducted during the current year: 
Here we will first describe, in sequence, a series of experimental 
procedures that lead to labeled antibody preparations that provide evidence of 
preferential labeled antibody localization in rat mammary tumors. We extended 
our studies on antibody purification by absorbing and eluting the polymerized 
normal rat tissues (excluding mammary tissue) at pH 3.2. Protein determination 
was followed on each eluate by the Lowry method, until the optical density in 
eluate was equal to the blank. A total of 3 absorptions and elutions were required. 
IGg was prepared from 5.0 ml of a rabbit immunized with first generation carcinogen 
induced Line 1 mammary tumor membrane preparation. This IGg was absorbed and 
eluted onto the 3X absorbed and eluted polymerized normal rat tissues. The eluted 
IGg was then absorbed and eluted onto polymerized tumor membranes, which had 
been previously absorbed and eluted 3X at pH 3.2. Eluate was concentrated by 
negative pressure dialyses. Protein content was assayed and labeled with 125 1. 
The total protein recovered was 1.6 mg on 0.5 ml. For labeling we used a modi-
fication of the IC1 microiodination method (in press). Briefly, this method 
is as described for the microiodination, except in these iodinations we used 
the 1251 con-V shipping vial to carry out the iodination. 2.62 mCi of 125 1 were 
attached to the antibody. This labeled antibody was in vivo purified in 2 male 
F-344 rats for 24 hours. Rats were on non-radioactive KI drinking water 24 hours 
before 1.2 mCi of labeled antibody was IV injected. Rats were bled to death 
by heart puncture. Serum was collected and pooled. A total of 105 pCi of labeled 
antibody was recovered in the sera. Ninety-three pCi of this in yivo screened 
antibody was absorbed and eluted onto 3X eluted polymerized tumor antigen. This 
eluted labeled antibody contained 1.8 lied_ of 125 1. The per cent elution was 
64.2 and the overall yield was 1.93%. In vitro testing showed that this labeled 
antibody had slightly decreased the uptake in the 2 tumor lines tested, and a 
marked decrease in normal rat and rabbit kidney. When in vivo testing in F-344 
mammary tumor bearing rats, tumor localization did not increase but normal mammary 
gland tissue showed localization close to the values found in tumor. These values 
will be given in the next section. As Dr. Bale pointed out this purification 
1 
system thus far described may be attributed to antigens that are not present 
on the tumor cell surface or are otherwise masked in vivo and thus this antibody 
does not preferentially bind in tumor after intravenous injection. Another 
possibility is that organ specific antibodies react with antigen(s) or with 
circulating blood components and are catabolized before they reach the tumor; 
these possibilities are indicated by the high levels of radioactivity found in 
the spleen and liver. 
Reisolation of labeled antibody bound to tumor. A similar antibody 
purification and 125 I-labeling was done. This labeled antibody was sephadex 
G-200 filter. IGg fractions pooled. . To this 125 1-labeled antibody, 1311 in 
vivo ,screened normal rat IGg was added. This mixture was given IV to 4 F-344 
bearing subcutaneous mammary tumors. All rats were sacrificed by guillotine. 
One rat was killed 24 hours after injection, 2 were killed at 65 hours and one 
at 164 hours. 1251 and 131 1 content of blood, tumor and other rat tissues was 
measured, then calculated as a per cent of the injected dose in tissue equal 
to 1% of the rat weight. 1251 values for representative tissues follows: for 
24 hours, blood 0.75, tumor 0.96 and 0.99, mammary gland 0.90, spleen 3.41, liver 
1.34, kidney 1.31, skin 1.08 and muscle 1.03. Tumor weight was 1.16 grs. The 
average for the 2 rats killed at 64 hours follows: blood 0.69, tumor 0.80, mammary 
gland 0.98, spleen 3.86, liver 1.14, kidney 1.30, skin 0.91 and muscle 0.91. 
Average tumor weight was 1.82 gr. For the rat killed at 164 hours values were: 
blood 0.53, tumor 0.76, mammary gland 0.05, for 125 1, no 131 1 was found, spleen 
14.35, liver 1.14, kidney 1.61, skin 0.61, muscle 0.79, tumor weight was 10.56 
gr. After the 125 1 and 131 1 content in tumors was counted, each tumor was homo-
genized in 0.85% NaCl, and then centrifuged. 125 1 and 131 1 contents in residues 
and supernates were measured and then calculated as per cent of the injected 
dose in tissue equal to 1% of the rat weight. 1251 found in residues of 24, 
65 and 164 hours were 2.38, 2.71 and 1.35; in the same order amount of 125 1 found 
in supernates were 0.61, 0.53 and 0.46. Although these values seem higher, they 
are still too low to be of any use for antigen isolation. The antibody preparations 
we were able to obtain do show moderate preferential localization, and to some 
extent some avidity for mammary tumor after 165 hours. 
Accumulation of 125 1-labeled normal rabbit IGg in the extravascular-
extracellular space in tumors and normal tissues. Dr. Bale was, for many years, 
interested in the extravascular-extracellular space in experimental rat tumors. 
(He directed two Ph.D. theses in this subject.) To further document these studies, 
we implanted a DMBA induced mammary tumor subcutaneously into the right flank 
of F-344 rats, and studied the accumulation of 125 1 and 131 I-labeled normal rabbit 
IGg. Both 125 1 and 131 I-labeled normal rabbit IGg were labeled by the IC1 micro-
iodination method. Both radioactive y-globulins were in vivo screened for 24 
hours. Rats were on non-radioactive KI drinking water 24 hours before 100,000 
cpm/0.5 ml of 125 I-labeled y-globulin injection was given IV. Twenty-four hours 
later 100,000 cpm/0.5 ml of 161-labeled y-globulin was IV injected. Rats were 
killed by guillotine 10 minutes after the last injection. Distribution of 1251  
and 131 1 in blood and tissue is given as a per cent of the injected 125 1 and 
131 I doses found in blood or tissues equal to 1% of the rat weight. 125 1 tumor 
to blood ratio were higher by a factor of 15 in tumor, ratios for 125 1 organ to 
to blood were in the order of 1 to 2 for spleen, kidney, liver and lungs. 
Additional experiments were carried out in DMBA induced tumors implanted surgically 
into the F-344 rats' liver. In these studies rats were given 125 1-in vivo  
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screened labeled normal rabbit IGg, then 1 or 2 days later sacrificed by 
perfusion with 0.85% NaC1 through the vena cava. Data are given as the ratio 
of 125 1 found in tumor or liver/ 25 I found in blood in per cent of the injected 
dose equal to 1% of the rat weight. The amount of 1251 found in tumor was 
0.49 and for normal liver 0.06 for rats sacrificed after 24 hours. For rats 
sacrificed after 48 hours the values for tumor were 0.35 and for normal liver 
0.067. Additional experiments were carried out in surgically implanted tumors 
in the F-344 rat's kidney. Results were similar to those found for subcutaneous 
and liver tumors. These data, although limited, seem to indicate that tumors 
growing in the liver and in the kidney may sequester injected y-globulin in 
the extravascular-extracellular space in a way closely resembling subcutaneous 
implanted tumors. Values for tumor, liver and spleen were lower than those 
obtained with tumor specific antibody. It is possible that our preparations 
of organ and tumor specific antibodies reacted with antigen circulating in 
the blood stream before reaching the tumor. Our results indicate that this 
property of tumors may be of use in overcoming one of the major difficulties 
associated with therapy of human cancer tumors inside the abdomen and thorax 
metastatic growth. 
Immunological technique for removing labeled normal rabbit IGg.from  
tumor-bearing rat circulation. We spent most of this year on this technique. 
This technique originally developed by Spar and co-workers in Dr. Bale's 
laboratory has been used to remove 131 I-labeled rabbit antibody to rat fibrin 
at a desired time from the circulation of the rat. In these studies we modified 
the technique developed by Spar and co-workers by careful in vitro titration 
of the goat-anti-rabbit IGg, in terms of mg. of protein. Then rats bearing 
kidney tumor surgically implanted were IV injected with an in vivo screened 
125 I-labeled normal rabbit IGg supplemented by rabbit serum containing the 
corresponding amount of y-globulin to be expected in the rat circulating blood. 
Twenty-four hours after injection, a second IV injection of goat antibody 
to rabbit y-globulin containing the predetermined units of goat antibody needed 
to procipitate all rabbit IGg circulating in the rat blood was given. Rats 
were killed by guillotine 30 minutes after the second injection. Our results 
indicate that the second antibody lowers the blood values by a factor of 10. 
Values for kidney tumor were 2-3 higher than blood, and for abdominal metestases, 
the ratios varied from 3-10. For normal kidney the ratio was close to blood 
values. For mesentery enlarged lymph nodes the ratio was increased by a factor 
of 6. Lungs, spleen and liver values were higher by a factor of 1, 12, and 
10 respectively. These studies were compared with rats sacrificed by perfusion 
instead of guillotine. These results showed very little difference except 
for liver, kidney and lungs, ratios were lower. 
This immunological technique was also carried out in F-344 rats bearing 
surgical tumor implants in the liver. In these experiments all rats were 
perfused. Results were similar to the values found for kidney tumor, except 
that in the case of liver implanted tumors the number of metastases found 
was increased. 
Although the results of these studies are difficult to summarize, 
if one considers that these studies were done in an attempt to reproduce a 
human metastasizing tumor in the rat, our results seem to indicate that the 
extra-vascular-extracellular compartment in tumors, whether the tumor is 
implanted subcutaneously or in abdominal organs, does sequester y-globulin 




Our results indicate that our preparations of organ-specific antibody 
do localize to some degree, in mammary gland and mammary tumors, but the degree 
of localization may depend on the burden of circulating antigens in the blood 
and also in the rate of exchange into the extravascular-entracellular space 
of tumors. This possibility was confirmed by the immunological technique 
in which liver and spleen values were comparable to the high values obtained 
with organ specific antibody while tumor values were slightly higher for our 
preparations of organ-specific antibodies. Also our preparations of labeled 
antibody bind strongly to tumors. This was shown by the 125 1 found in tumors 
5 to 6 days after intravenous ,injection of labeled antibody. 
Some possibilities for the immunological technique. One of the most 
common diagnostic tools for human cancer is CEA (carcino-embryonic antigen). 
It may be possible to obtain better photoscans if CEA circulating antigen 
in the blood stream of the patient is first removed by cold CEA antibody then 
24 or 48 hours later the 131 1-labeled CEA goat antibody is administered. 
Reports in the literature indicate that 131 1-labeled CEA antibody is capable 
of showing up in scans even though the patient has high levels of circulating 
CEA antigen, and the amount of 131 1 found in tumor is 0.001% of the injected 
dose. Our tumor and organ antibody preparations in terms of per cent dose 
per gram are closer and above 1.0. 
4 
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[22] Iodine Monochloride (IC1) Iodination Techniques 
By M. ANGELES CONTRERAS, WILLIAM F. BALE, * and IRVING L. SPAR 
For labeling proteins and related substances in solution with 131 1 or 
1251. the use of the ICI isotopiC exchange procedure may often be the 
method of choice. The actual procedure is simple, since the reagents used 
are stable over long periods of time. In this technique the total amount of 
iodine incorporated into the iodinated material is known and can be con-
trolled, and it avoids the use of oxidizing agents that may damage protein. 
These advantages were pointed out by McFarlane,' who developed an 
early version of this labeling procedure. 
The basic method, as it is most widely used today, 2 is as follows: ' 3 'I or 
' 251 in the form of iodide ions (often described by commercial sources as 
Nal) are mixed with the protein solution to be iodinated, buffered to a pH 
of approximately 8. An appropriate amount of ICI, in a weakly acidic 
NaCI solution, is then stirred rapidly with the protein—NaI mixture. The 
total buffering capacity must maintain the entire mixture at a pH of ap-
proximately 8. 
As a result of this addition of ICI. two reactions occur. Radioactive 
iodine, e.g.. ' 25 1, present as iodide, is converted to 125 1C1 by very rapid 
chemical exchange with nonradioactive ICI. Iodination of protein takes 
place; it can be considered to occur as a result of the following reactions. 
ICI ± NaOH —› HOl = NaCI 
HOI 	tyrosine residue 	iodinated tyrosine residue 	11•0 
This latter reaction is also rapid, so in 1 min a protective protein may 
be added and the labeled preparation be removed from the reaction vial. 
Scope of Usefulness 
Since the only oxidizing agent present during the iodination procedure 
is the ICI itself, no harm can come to protein that would be produced by 
other oxidizing agents. This contrasts with the oxidizing effects of chlor-
amine-T used to oxidize iodide to iodine in the labeling procedure of that 
name. This advantage may sometimes be important when working with 
labile proteins. Since the amount of total iodine incorporated in the la- 
- Deceased. June 28, 1982. 
' A. S. McFarlane, Nature (London) 182, 53 (1958). 
W. F. Bale. R. W. Helmkamp, T. P. Davis. M. J. Izzo, R. L. Goodland. M. A. Contreras, 
and I. L. Spar. Proc. Soc. Exp. Biol. Med. 122, 407 (1966). 
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beled protein can never exceed the amount added as ICI, this sets an 
upper limit on the average number of iodine atoms attached to each mole-
cule of labeled protein. This level of attached iodine is sometimes uncer-
tain by other labeling procedures, since it cannot be readily controlled. 
Three variants of the basic ion-exchange ICI iodination method will be 
considered. First to be described is a macro method in which the amount 
of protein to be labeled amounts to several milligrams, and the volume of 
solution in which it is contained is in the range of a few milliliters. This 
procedure is easily adapted to remote handling techniques behind y-ray 
shields and has been used for attaching to 4 mg of immunoglobulin (IgG) 
100 mCi or more of 131 1. Second to be described is a micro method for 
labeling amounts of protein ranging from less than 100 ,u.g to several 
milligrams. The volume of the product after completing the labeling oper-
ation can be held to less than 1 ml. It is a good general procedure, but has 
not yet been adopted for remote shielded handling of large amounts of 
radioactivity. The third procedure to be described is a variant of the 
second in which the labeling procedure is carried out directly in suitable 
1251 or ' 3 'I shipping vials. Finally there will be a short discussion of tech-
niques in which radioactive ICI is produced by oxidation of total iodide in 
radioactive Nal preparations. 
Investigators proposing to use the ICI method for labeling should be 
aware of two limitations of this method. Since in this procedure no oxida-
tion of iodide ion is carried out in the presence of protein to be labeled, 
any reducing substances present can compete for positive iodine with this 
protein. Therefore the presence of such substances should be kept low. 
Also. the ICI method has not been found to be a useful procedure for 
directly labeling cells or cell membranes; it is useful in preparing reagents 
for other types of 1251 or 131 1 labeling—e.g., the preparation of diazotized 
diodosulfonilic acid for labeling of cell membranes. 3 
Reagents 
Iodine Monochloride Reagent. A convenient stock solution of ICI is 
0.02 M in ICI, 2.0 M in NaCI. 0.02 M in KCI, and 1.0 M in HCI. It should 
be noted that iodine monochloride has a long history as a convenient term 
for referring to what is more strictly the hydrochloric acid solution of the 
trihalide ion (ICli). As described more fully elsewhere,' it can be pre-
pared as follows: To a solution of 0.5550 g of KI, 0.3567 g of KI0 3 , and 
29.23 g of NaC1 is added 21 ml of concentrated HCl (sp. gr. 1.18) and 
water to make the volume to 250 ml. The slight amount of free iodine is 
3 R. W. Helmkamp and D. A. Sears. Int. J. Appl. Radio:. Isot. 21, 6S3 (1970). 
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then removed by passing through the solution a current of air saturated 
with water vapor for a few hours. It is worthwhile to ascertain that the air 
for aeration is truly saturated and that no reduction in volume occurs 
during this aeration procedure. Completeness of free iodine removal is 
tested by extracting a few milliliters of the ICI preparation with C0 4 . The 
separated CC1 4 fraction should be colorless with only a faint pink blush 
when the extraction is complete. If care has been taken that the air being 
used for iodine extraction is fully water saturated, the final la solution 
should be within 1% of the calculated 0.02M value. It is indefinitely stable 
at room temperature. The exact molarity of the solution can be deter-
mined by adding an excess of KI to an aliquot and titrating the liberated 
iodine with a standardized thiosulfate solution. 
1251 Solutions. Several sources of r25 I-labeled iodide solutions are avail-
able suitable for use by procedures described here. High specific activity 
preparations prepared without reducing agent are preferable. For use with 
the micro method, some necessary restrictions on volume and alkali con-
tent will be given later. 
Some quantitative knowledge of the characteristics of 125 1 are needed 
in setting up procedures that give a satisfactory degree of 125 I coupling to 
protein and little or no damage to the labeled protein by attaching too 
much iodine to it. Pure 1251 contains 4.596 x 10 -7 mole or 57.44 x 10 -6 g of /7- 
iodine per Curie, which by definition is undergoing 3.7 x le disintegra- 
tions per second. Let it be assumed that 10 mCi of 125 1, 4.596 x 10 -9 mol, 
without additional iodine present as impurity, is used to label 4 mg of IgG. 
and that 4 mol eof ICI are used per mole of protein (that is, 4 molecules of 
ICI per protein molecule). Four milligrams of this protein equals 2.5 x 
— 10 -8 mol l, and the ICI to be used is 4 x 2.5 x 10 -8 = 1.0 X 10 -7 mol. Thus —
after complete isotopic equilibrium has been reached in the exchange 
reaction between iodide and ICI, the fraction of ' 21 available for labeling 
will be (1.0 x 10-7)41.0 x 10 -7 + 4.596 x 10 -9 ) = 0.9541 = 95.6%. 
Even when the amount of IgG to be labeled is reduced to 1 mg, and the 
amount of 10 is reduced accordingly, still most of the ' 251, in this case 
84.5% is available for labeling. The situation changes significantly when 
0.1 mg of IgG is to be labeled with 10 mCi 1251, at the previously consid-
ered ratio of 4 mol Pof ICI to 1 mol lofIgG (1 ICI molecule , per 40,000 
daltons protein). The protein represents 6.25 x 10 -1° moVof IgG, and — 
the corresponding IC1 equals 2.5 x 10 -9 mol. Thus, after the exchange 
reaction is completed, the fraction of 125 1 available for labeling will be 
(2.5 x 10 -9 )/(4.596 x 10 -9 + 2.5 x 10 -9 ) = 0.352, or 35.2%. 
The fraction of 125 1 available for iodination can be increased by using 
larger amounts of ICI, but at the same time increasing the possibility of 
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ing of hormones with ' 751 by the chloramine-T method for radioimmunoas- 
say is often carried out at levels of 50-100 mCi of 1751 per milligram of 
protein.4 r/r/ 
r 	 — - I 31/ Solutions. Stable 1771 and 1291 (1.6 x 10 -7 year half-life) are pro- 
,,,j4/,,,, ?e( 5 3 ' -'44 	duced in substantial amounts. 75 when 131 1 is produced by neutron activa- 
-', tion of normal tellurium, probably the method most used at the present 
it a, ; 
time If the neutron radiation time is 24 hr, and the resulting iodine is 
processed and shipped during the next 48 hr, the iodine at shipping time 
would be 44% 1771, 23% 1291, and 33% 131 1. Thus, in practice, it is difficult to 
obtain and use in the laboratory 1311 in which the 131 1 exceeds 20% of the 
total iodine content. 
Increases in the time of irradiation and delays in processing, shipping, 
and use can lead to large increases in non- 131 I iodine. For example, if the 
neutron irradiation time is 10 days, and the time before use for iodination 
another 8 days, 131 1 will amount to only 12% of the total iodine. Occasion- 
. 	
ally iodine obtaiNdA 
0/
rom suppliers contains substantial amounts of nonra- 
— dioactive iodineAhave been added to minimize absorption effects. Such 
iodine is entirely unsuited for labeling purposes, and the labeling efficien-
cies achieved are close to zero. 
Iodine-131 less diluted by other iodine isotopes can be obtained as 
iodine produced by uranium fission. Such iodine has been used in experi-
mental and clinical cancer therapy attempts with antibody carrying doses 
of 131 1 in the therapeutic range. 6•7 Tellurium, highly enriched in 170Te, 
which was produced at Oak Ridge National Laboratory, would be an ideal 
source for 131 1 production. By this latter procedure, iodine could be pro-
duced that would be almost entirely 131 1. 
Borate Buffer. This buffer, pH 8, is prepared by adjusting a distilled 
water solution of 0.16 M NaCI and 0.20 M H 3 B03 with 1.6 M NaOH to pH 
8, with a final NaOH concentration of approximately 0.04 M. Borate 
buffer with twice these amounts of NaCI and H 3B03 , adjusted to pH 7.65 
with 1.6 M NaOH, is termed 2x borate buffer. When diluted with an 
equal volume of distilled H2O, the pH becomes 8. 
Protein Solutions for Labeling. The protein to be labeled is dissolved 
or dialyzed against borate buffer. The ,glycine buffer suggested by Mc-
Farlane.' is also satisfactory but gives slightly lower labeling yields. As 
D. N. Orth. this series, Vol. 37, p. 22. 
5 W. F. Bale, R. W. Helmkamp, T. P. Davis, M. J. Izzo, R. L. Goodland. and I. L. Spar, 
"High Specific Activity Labeling of Proteins with "'I," Report UR-604, AEC TID-4500 
(16th ed.). 1962. 
6 I. L. Spar. W. F. Bale. D. Marrack, W. C. Dewey. R. J. McCardle, and P. V. Harper. 
Cancer 20, 865 (1967). 
W. C. Dewey, W. F. Bale. R. G. Rose, and D. Marrack, Acta Unto Int. Cancrum 19, 185 
(1963). 
)NG 
[22] 	 ICI IODINATION TECHNIQUES 	 281 
noted earlier, any reducing substances present in the iodination mixture 
can compete with tyrosine residues for positive iodine. One common 
source of such reducing substances is cellophane dialysis tubing, particu-
larly if the substance to be labeled has been concentrated in such tubing 
under reduced pressure. Therefore, if dialysis tubing is used, it should be 
purchased or extracted so as to be as free of reducing substances as 
possible. Proteins concentrated by reduced-pressure dialysis in cello-
phane or other membranes containing reducing substances that may be 
solubilized, should be dialyzed further to remove such reducing sub-
stances. 
Under some conditions to be mentioned later, dialysis against 2x 
borate buffer may be preferable because of its greater buffering power. 
Gel Separation Columns. For separating bound and unbound radioac-
tive iodine, Sephadex G-25 or G-50 may be used. The size of the column 
should be such that an adequate separation is achieved between the frac-
tions containing the labeled protein and the unreacted iodine or iodate. It 
is best to first ascertain the void volume with Blue Dextran and the point 
of inorganic iodine breakthrough using a small test sample of unreacted 
radioactive iodide. When passing the final labeled preparation through the 
column. the first burst of radioactivity should appear just behind the void 
volume for proteins in the immunoglobulin size range. 
Ion Exchange Column. Dowex I-X4 resin (50-100 mesh) is allowed to 
stand in contact with I N HCl for several hours, then washed successively 
with 20% NaCI solution, 0.85% NaCI solution until the filtrate is neutral, 
and then stored under the latter solution. A column is formed by placing 
2.5 ml of this resin in a 3-ml disposable syringe containing a small plug of 
glass wool. The syringe is filled with 0.85% NaCI and then drained just 
before use. 
It was found that such a column removed all iodide ions from an 
iodinated protein solution, and that no significant iodide ion was eluted on 
subsequent washing of the column with 1.5 ml of normal rabbit serum or 
0.5 ml of this serum followed by 1 ml of saline solution. Despite this rinse, 
however. 4-8% of the iodinated IgG was still retained by the resin. 
Catalase Solution. Sterile preparations, without preservatives, assay-
ing 30.000 units or more per milligram of protein are used to destroy 11202 
 that is sometimes present in high-activity commercial 131 1 preparations. 2 
Macro Method for 1251 or "'I Labeling 
Apparatus 
The setup shown in Fig. 1 is widely used for low and high level labeling 
with 13 '1 and 125 1 and is well adapted for remote handling and good radia- 
8 CM GLASS WOOL 
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FIG. I. Apparatus for iodination by the macro technique. Test tubes used at location A 
can be of any appropriate size to hold reagents. C is a 2.2 cm internal diameter x 15 cm 
Pyrex test tube. B is a 0.1 cm internal diameter capillary tube, slightly constricted at the end 
in tube C. Its effective aperture is such that the application of strong suction through D µill 
jet 5 ml of water from A to C in about 1 sec. 
tion shielding for 131 1 preparations in the 100-300 mCi range. A combina-
tion of lead bricks and transparent lead glass shielding, of thick-walled 
lead tube holders, and remote-handling grip tools that can work around 
corners make isotopic labeling followed by ion exchange or molecular 
sieve passage possible with negligible exposure to the operator. 
This procedure will first be described for labeling 4 mg of IgG, as-
sumed molecular weight 160,000, dissolved in or dialyzed against borate 
buffer, with 4 equivalents of Ia. This is a level of 1 ICI molecule per 
40,000-dalton protein. 
The necessary dilution of ICI from the 0.02 M stock solution is calcu-
lated, and a subdilution is made as follows: 4 mg of IgG represents 
2.5 x 10-8 mol of protein; four equivalents of la is therefore 1 x 10 -7 
 mol. To provide this amount of ICI in 0.2 ml of solution, a dilution con-
taining 5 x 10-7 molml is needed. One milliliter of the stock ICI solution 
will contain 0.02/1000 = 2 x 10 -5 mol. Therefore the dilution factor 
needed will be (2 x 10 -5 )45 x 10 -7) = 40. 
Step 1. To make this dilution 0.2 ml of the stock ICI solution is mixed 
with 7.8 ml of 2 M NaCI solution already added to a clean disposable test 
tube. (In a labeling procedure where a different amount of ICI is required, 
the dilution is calculated and made in such a way that the required amount 
of ICI is present in 0.2 ml of solution close to 2 M in NaC1.) 
Step 2. The protein to be iodinated, in a volume of 3 ml or less, is 
placed in tube C, and the iodination apparatus is assembled. Alterna-
tively. it may be added by suction through tube B after the apparatus is 
assembled. 
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Step 3. The radioactive Nal solution, made to a volume of 2-3 ml with 
borate buffer, is added to the protein solution by suction. 
Step 4. Immediately 0.2 ml of the subdilution of ICI prepared under 
step 1 is added to 1.8 ml of 0.85% NaCI solution and mixed. Then, by 
rapid suction, this preparation is added as a jet to the iodine—protein 
solution. 
Step 5. Labeling occurs rapidly, so 1 min later, 1 ml of protective 
protein (20-60 mg) is added to protect against radiation effects and de-
struction of protein that may occur by such phenomena as surface dena-
turation in dilute solution. Typical protective proteins used are 6.25% 
solutions of human or animal albumin, citrated human or animal plasma, 
normal serum, or a solution of gelatin. 
Unbound radioactive iodine can be removed from the labeled prepara-
tion by ion-exchange resin, dialysis, or passage through a suitable gel 
filtration medium, such as Sephadex G-25. 
The ion-exchange resin is probably the easiest to use for moderate to 
high molecular weight proteins such as IgG. After passage of the labeled 
preparation through the resin at the rate of about 1 ml/min, the resin is 
rinsed with an additional 1-1.5 ml of protective protein. This procedure 
has a disadvantage in that the resin does not retain iodate, and with a rinse 
of 1 ml of normal serum it still retains a few percent of IgG. However, the 
presence of iodate is rarely, if ever, a practical problem, except in old 125I-
labeled preparations. Also, it can be tested for by a preliminary passage of 
a small portion of the radioactive preparation to be used for iodination 
through the resin. Iodide will be retained by the column, but iodate will 
come through in the first 10 ml of the effluent. If the iodinated material is 
one retained by the resin, such as insulin, glucagon, and many other 
substances of relatively low molecular weight. dialysis or gel filtration can 
be used. Dialysis has the disadvantage that dialyzable radioactive iodine 
is distributed through large volumes of fluid that may present a disposal 
problem. 
Radioisotope calibrators, of the type used in nuclear medicine, are 
convenient for measuring the 131 ] content of different fractions during 
iodination procedures, but almost any equipment capable of giving good 
relative y-ray intensity measurements can be utilized. 
This general procedure has proved to be well adapted for the attach-
ment of 13 '1 to antibody for the purposes of human cancer therapy. Here it 
is desirable that relatively large amounts of 131 1 be attached to protein, 100 
mCi or more for individual patients. so that the amount of administered 
foreign protein can be kept small, not more than 4-5 mg if possible if the 
antibody is a protein of xenogenic or allogenic origin, to slow or avoid the 
possibility of allergic sensitization. Up to the time iodination is complete, 
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the 131 1 is transferred only by suction into closed containers, greatly re-
ducing the possibility of radioactive aerosol formation. Equipment can 
easily be devised for carrying out the necessary procedures in a hood 
behind shields of lead or lead glass. 
Use of Catalase 
In earlier versions of the ICI iodination procedure, 8 in which radioac-
tive ICI was formed first and then jetted into the substance to be labeled, it 
was found that hydrogen peroxide generated by the action of 131 1 /3-rays 
on water, first oxidized any reducing substances present and then pro-
duced free FLO, that was able to destroy ICI. This reduced or prevented 
iodination. This H202 effect is reduced by the procedure in which ICI is 
added to the protein mixture, as described here, but this effect has not 
been studied at high 131 1 levels. Catalase under these circumstances may 
still be useful in increasing 131 1 iodination efficiency. As noted earlier, the 
catalase preparation should be of such purity that the amount used should 
be. in total protein content, a very small fraction of the material to be 
iodinated with 131 I. 
To use catalase for H 202 destruction before the labeling procedure is 
carried out, the Na 13 II solution should first be adjusted to approximately 
pH 8; 600 units of catalase are added, the mixture is allowed to stand for 
10 min, and then step 3, the addition of the Na 131 1 to protein, is carried 
out. Protein, added as catalase, is 0.5% or less of the 4 mg of protein to be 
coupled to 131 1. 
Micro Method for Radioactive Iodine Labeling 
The apparatus shown in Fig. 2 can in principle, and often in fact, be 
used for labeling protein in approximately the same amounts as in the 
macro :::;:thod just described. However, procedures have not been devel-
oped for using it in a completely shielded operation. It has the advantage 
that. since the volumes used are small compared to those used in the 
macro method, protein concentrations can be kept higher during equiva-
lent labeling procedures, and the effects of surface denaturation can be 
reduced. 
The general procedure adopted to labeling 0.,1-mg portions of IgG with 
—1-mCi amounts of 1251, and some of the, precautions to be taken, is as 
follows: 
Step 1. A 1-inch, 21-gauge needle is inserted partially (0.5 inch) 
through the vial septum, and a 3.0-m1 disposable syringe barrel, packed 
a R. W. Helmkamp, R. L. Goodland, W. F. Bale. I. L. Spar, and L. E. Mutschler, Cancer 
Res. 20, 1495 (1960). 
LONG 
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FIG. 2. Apparatus for iodination by the micro technique. A is the iodination V-vial.* B is 
the magnetic stirrer top. C is a triangular matrex Teflon-coated magnetic stirrer bar.* D is a 
self-sealing laminated disk.* E is a 21 gauge. 1-inch needle attached to a 3-ml disposable 
syringe barrel that has been packed, not too firmly. with glass wool. F represents a series of 
three hypodermic needles and syringes used in sequence during the iodination procedure. 
Stainless steel needles are recommended because of their greater strength. Lock-type sy-
ringes and stainless steel needles should be used when possible. Two-inch, 18 gauge needles 
are required for removing the labeled material from the iodination vial and often are neces-
sary in transferring radioactive iodine from the shipping container to the iodination vial. 
* Purchased from Pierce Chemical Co.. Rockford. Illinois. 
with glass wool, is attached to the needle. (This step may be omitted if 
great care is taken that subsequent steps are conducted in such a way that 
positive pressure does not build up inside the vial). 
Step 2. Preparation of Diluted ICI. The amount of protein to be la-
beled by this procedure, 0.1 mg, is 1/40th (2.5%) of the amount used with 
the macro procedure just described. Therefore at the same protein: IC1 
ratio used for the macro procedure. an additional 1 :40 dilution will be 
required. This is obtained by making the first 1 :40 dilution described 
under the macro procedure. It will be used for making a further 1 :40 
dilution by mixing 0.2 ml of this preparation with 0.85% NaCI solution as 
a part of step 5. 
Step 3. The protein to be labeled, preferably not exceeding 0.2 ml in 
volume, is added with a tuberculin syringe that is equipped with a 20-
gauge needle and has been prerinsed with borate buffer. 
Step 4. The Na 1251 solution, preferably not exceeding 0.2-0.3 ml in 
volume, diluted if necessary in borate buffer, is added with a syringe 
attached to an 18-gauge needle prerinsed with buffer. If feasible, it is 
1 LP\ 
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desirable that the needle be locked to the syringe, since accidental disen-
gagement at this union has been the site of at least one iodine spill. 
Step 5. Iodination. The rotating vane is actuated briefly to mix protein 
and 125 1 solutions. Then the final dilution of ICI is made by mixing 0.2 ml 
of the first 1 : 40 dilution to a tube containing 7.8 ml of 0.85% NaCI solu-
tion. Then 0.2 ml of this 1 : 1600 dilution of the stock IC1 solution is drawn 
into a tuberculin syringe and, with the vane rotating briskly, expelled 
rapidly through the septum into the Na 125I—protein mixture. The vane is 
stopped after 2-3 sec. 
Step 6. One minute later, protective protein is added and the labeled 
protein is withdrawn with a syringe with a lock-type attachment to a 2- 
inch, 18-gauge needle. The labeled protein is passed through the resin 
column or another equivalent method for removing unbound radioactive 
iodine. The reactive vial is then rinsed with an additional amount of pro-
tective protein that is passed through the inorganic iodide removal appa-
ratus. 
Labeling in Shipping Containers 
Some shipping containers, for example, the Combi-V-Vials supplied 
by New England Nuclear, can be used directly as reaction vessels for 
iodination. The main requirements are (a) a self-sealing septum through 
which reactants can be added and removed; (b) a vial volume adequate to 
accommodate the necessary reagents and mixing procedures; and (c) a 
method for rapid mixing during the addition of IC1. Experience shows that 
a Genie-Vortex mixer can be used with the Combi-V-Vial to provide such 
mixing. However, it is desirable to carry out preliminary tests with a 
nonradioactive vial and visual control to assure that mixing is adequate 
with the volumes of reactants used during the iodination procedure. 
This third method, a modification of the micro procedure for labeling 
0.1 mg of protein with 10 mCi of 121, will not be described. 151 should be 
shipped at high concentration (>350 mCi/m1) in 0.1 N NaOH. Protein to 
be labeled should be dissolved in or dialyzed against borate buffer at as 
high a concentration of protein as feasible and then diluted in borate 
buffer (made from water and 
mi
ankl reagents free of reducing substances) to a 
level of 0.5 mg of protein,i lliliter. 
Step I. A 1 :40 dilution of stock 0.02 M ICI is prepared as described 
under step 2 of the micro iodination procedure. 
Step 2. Protein to be labeled, 0.1 mg in a-volume of 0.2 ml, is injected 
with a syringe into the vial containing Na 125 1, and the two components are 
mixed. This may be done by inversion of the vial after the protein addi-
tion, to wash down any 1251 adhering to top of vial, or by a preliminary 
centrifugation before adding the protein. 
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Step 3. Iodination. This step is the same, in principal, as the step 5 of 
the micro iodination procedure. The final dilution of ICI is made by mixing 
0.2 ml of the 1 :40 dilution with 7.8 ml of 0.85% saline. Then, while the 
125I-protein mixture in the shipping vial is swirled with the Vortex mixer, 
0.2 ml of the final ICI dilution (1 :.1600) is added rapidly by syringe. The 
mixing is stopped in 3-4 sec. 
Step 4. One minute later. the protective protein is added. The continu-
ing procedure is the same as described under step 6 of the micro pro-
cedure. 
)NG 
Iodination Using Radioactive ICI Produced by Oxidation of Total Iodine 
in Nal Preparations 
Helmkamp et al.9 have described a method for converting 131 1 of Na' 3 'I 
preparations quantitatively to ICI. No exchange reaction is involved. The 
original paper should be consulted for details. It has the advantage that all 
the radioactive iodine can be utilized for iodination, no matter how much 
there may be. This technique has the corresponding disadvantage that the 
actual amount of total iodine incorporated in the labeled material will be 
unknown unless one knows in advance the total iodine content of the 
Na 131 I preparation used. Helmkamp and co-workers'° have also devel-
oped a technique for determining the total iodine content of such Na' 31 I 
preparations. 
In this labeling procedure initially designed for labeling 4 mg of y-
globulin with 50-200 mCi of ' 31 I, any 14,02 present in the Nal 31 I prepara-
tion is destroyed by catalase. The solution is then made acidic (pH ap-
proximately 3) with 0.25 N NCI. Saturated NaCI solution and I NNCI are 
then added in amounts such that, on subsequent addition of KI0 3 contain-
ing 5 times the estimated total iodide content of the Nal 31 I preparation 
used for labeling, the solution will be approximately 0.05 N in NCI and 1 
M in NaCl. Under these conditions the iodide ion is converted to IC1 with 
reasonable rapidity; the iodate ion undergoes a negligible amount of ion.  
exchange. Thus at the end of 10 min that mixture can be adjusted rapidly 
by addition of a calculated amount of NaOH to a pH around neutrality 
and jetted into the solution to be iodinated buffered to a pH of 8. From 
then on, the procedure follows the ICI exchange procedure des‘Cribed 
above. 
Doran and Spar" have described an adaptation of the oxidative ICI 
iodination technique adapted to labeling microgram amounts of protein 
9 R. W. Helmkamp, M. A. Contreras, and M..1. Izzo. Int. J. Appl. Radial. hot. 13. 747 
(1967). 
to R. W. Helmkamp. M. A. Contreras. and W. F. Bale. J. Nucl. Med. 7, 491 (1966). 
II D. M. Doran and 1. L. Spar. J. Inununol. Methods 39, 155 (1980). 
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with ' 25 I to high levels of specific radioactivity. They include a review of 
the qualities of the iodinated proteins produced by the ICI and other 
iodination methods. 
Additional Considerations 
Although only two examples of labeling of proteins with radioactive 
iodine are discussed in detail, it is generally simple to extrapolate from 
them to suitable procedures for different amounts of protein to be labeled, 
different levels of radioactivity, alternative iodine isotopes, and different 
ratios of moles of iodine to moles of protein. 
In general, 125I can be substituted for 131 I, and vice versa, with no 
change in procedure. The amount of radioactive isotope used can vary 
from a small fraction of I kiCi to many millicuries provided volumes are 
kept to the described range and proper safety precautions are taken. The 
molar ratio of ICI to protein can be varied, except that one must take into 
account the fact that decreasing the molar ratio of ICI to protein increases 
the effect of reducing substances in a protein solution, and the fraction of 
radioactive iodine incorporated into protein may be reduced. 
It is important to calculate and carry out ICI dilutions so that a desir-
able molar ratio of IC1 to protein is used. It is common and reasonable to 
assume, with larger proteins, that one ICI per 40,000 daltons protein is a 
reasonable level. The examples given here, labeling at a level of 4 mole-
cules of ICI per IgG molecule of assumed 160,000 molecular weight. rep-
resents this level. There is, however, reported evidence that some pro-
teins, e.g., fibrinogen, are damaged at this level of labeling. When labeling 
proteins with a molecular weight less than 40,000, a molecular ratio of I 
between protein and ICI represents a reasonable starting point. A final 
criterion is that the labeled protein fulfills the function for which the 
labeling operation was carried out. 
Probably the macro method of labeling should not be routinely used 
for labeling less than 2 mg of protein. Low iodination yields may result, 
since reducing substances are not easy to eliminate from reagents. and in 
addition, surface denaturation may produce unacceptable protein dam-
age. On the other hand, the micro method has become the routine proce-
dure in our laboratory for labeling 4-mg amounts of protein with 10 mCi of 
1251 or 1311. 
It is necessary that the buffering capacity of the protein solution, or of 
the buffer added with it, be sufficient to bring the pH of the 1 =5 1 or 131 1 
solution to approximately 8, possibly from a much more basic pH, and 
then keep the reaction mixture at approximately pH 8 after addition of the 
acidic ICI solution. The procedures as described do not cover all possibili- 
[22] 	 ICI IODINATION TECHNIQUES 
	
289 
ties. As one extreme example, one investigator desired to iodinate, if 
possible, all tyrosine residues of a protein and used enough ICI to do so. 
This introduced so much acid with the IC1, that the yellow ICI color 
persisted and no iodination occurred. The remedy was to prepare and use 
an ICI of much higher molarity. Some investigators have attempted to use 
131 I solutions that contained so much base that the pH remained very high 
after adding the protein solution, and the protein was denatured and pre-
cipitated. 
Effect of Reducing Substances 
Use of ICI iodination techniques, with a ratio of 1 ICI molecule per 
40,000 daltons protein, never resulted in radioactive iodine attachment to 
proteins approaching 100%. There are probably multiple reasons for this, 
but the major one is reported to be the presence of reducing substances 
present as a part of the protein to be labeled or in the fluid where the 
reaction occurs. McFarlane' has suggested a preliminary oxidation of 
protein by iodine at pH 4.5 as a means of eliminating reducing properties 
of protein to be iodinated, but it has never been adopted as a working 
procedure. As noted earlier, one common source of reducing substances 
is dialysis tubing. In one series of experiments on the micro iodination 
teChnique, the use, as a diluent, of borate buffer that had been in contact 
with cellulose dialyzing tubing under various conditions reduced effi-
ciency of ' 25I coupling from values of about 50% to values ranging from 39 
to 2.5%. 
Importance of Rapid ICI Mixing after Addition 
If complete mixing has not occurred during the ICI addition to the 
radioactive iodine—protein mixture before the ICI has reacted with protein 
or has otherwise been destroyed, then some radioactive iodine will re-
main as unexchanged iodide and have no chance to react with protein. 
This will result in lower labeling effectiveness. In some experiments it can 
also lead to misinterpretation of results unless taken into account. For 
example, let it be supposed that the labeled preparation was an enzyme, 
and that the experiment was intended to determine whether labeling with 
approximately one atom of iodine per enzyme molecule would lead to 
complete loss of enzymic activity. If mixing were so incomplete that the 
ICI reacted with only one-half of the enzyme molecules, then 50% would 
still be unlabeled and would retain full enzyme activity, irrespective of 
whether one iodine atom per enzyme molecule could destroy enzyme 
activity, or not. 
L; 
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Radiation Damage 
Proteins are particularly susceptible to radiation damage when in di-
lute solutions, since the ratio of free radicals and peroxidies produced 
from irradiation of water to protein molecules is high. At a level of 10 
mCi/m1 the self-irradiation from 131 1 is at a level of about 4.000 rad/hr. In 
one study.'' 131 I-labeled rabbit antibody to rat fibrin was purified and 
irradiated with 60Co y-radiation or lightly filtered 250 KV X-radiation. In 
dilute solutions (less than 0.1 mg of protein per milliliter), 10,000 rad of 
60Co radiation rendered the uptake of the purified labeled antibody by rat 
fibrin to only 17% and at 40,000 rad to about 47%. Dosage of 200,000 rad 
of 60Co y-rays or 100,000 rad of X-ray reduced the ,specific uptake to 
virtually zero. At this latter dosage the presence of normal rabbit serum 
protein at a level of 8 mg per milliliter of irradiated solution reduced the 
radiation effects to approximately that produced by 10.000 rad. 
It is important immediately to minimize radiation damage once the 
iodination reaction is complete. Such protective measures are the addi-
tion of nonspecific inert protein, dilution, then freezing, which are com-
patible with the intended use of the iodinated protein. 
Efficiency of Coupling of Radioactive Iodine to Protein 
Data from our own and other laboratories indicate that the macro IC1 
procedure. when used to couple radioactive iodine to protein at protein 
levels of a few milligrams and ICI levels of one ICI molecule per 40,000 
daltons protein gives labeling levels of 50% or higher in most instances, 
usually at the 60-70% level. The major exceptions are instances where 
amounts of 131 1 in the 100 mCi or higher levels were used, and the total 
amount of iodine involved was great enough to render the IC1 exchange 
reaction an inefficient one. An extensive use of one adaptation of the 
macro method for insulin labeling gave preparations with relatively low 
efficiency of "'I or 125I coupling, but with reproducible production of 
biologically active insulin metabolized in a normal physiological 
manner.' 3 
The use of the micro method is now standard in our laboratory for 10 
mCi or less of radioactive iodine, and amounts of protein ranging from 0.1 
mg to 4.0 mg. Labeling efficiencies are similar to the macro method at the 
12 R. W. Helmkamp, R. L. Goodland, W. F. Bale, I. L. Spar, and L. E. Mutschler. "High 
Specific Activity Iodination of Gamma-Globulin with Iodine-131 Monochioride," Report 
UR-56S. AEC TID-4500 (15th ed.), 1960. 
13 J. L. Izzo. A. M. Roncone, D. L. Helton, and M. J. Izzo, Arch. Binchern. &whys. 198,97 
(1979). 
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level of 4 mg of protein, and much better, around 49-60%, when low 
millicurie levels of ' 251 are used to label 0.13 mg of protein. 
Isotopic Purity of 1311 Produced by Fission and from Tellurium 
One currently experimental, but potential future routine, use of 131 1 is 
as a therapeutic agent attached to tumor-localizing antibodies, either allo-
geneic or xenogeneic in nature. To diminish the amount of antibody that 
must be used, and keep low the possibility of allergic reaction, it is desir-
able to use 131 1 of as high a specific activity as possible. The most common 
current method for producing 131 1, the irradiation of tellurium with slow 
neutrons, unavoidably also produces stable 1271 and 1291 with a 1.6 x 107 
 year half-life. The highest specific activity 13 '1 currently available contains 
approximately 100 pg of total iodine per Curie, of which only 8µg is 131 1. 
Table I shows the composition of iodine obtained after neutron bom-
bardment of natural tellurium as a function of duration of irradiation and 
time after activation. Table II shows similar data for iodine produced by 
slow neutron-induced fission of " 5 U. Earlier= our laboratory was able to 
obtain from Oak Ridge National Laboratory fission-produced 131 1 with 
specific activities as high as 24 px, of total iodine per Curie of 131 1. 
Inspection of Table I shows that this high specific activity is scarcely 
possible with 131 1 obtained from natural tellurium. With sufficient demand, 
TABLE I 
ISOTOPIC PURITY OF PRODUCED FROM TELLURIUM' 
Percentage of total 
Activation Time after iodine Micrograms total 
time activation iodine 
•r1 (days) (days) per Curie 131 1 
1 2 44 23 33 25 
10 2 61 20 19 42 
20 2 66 20 14 59 
40 2 70 22 8 96 
1 8 51 26 23 36 
10 8 67 21 12 67 
20 8 69 1 2 9 93 
40 8 72 23 5 115 
Calculated relative amounts of neutron-induced iodine isotopes present 2 and 8 
days after activation of natural tellurium in iodine separated immediately after 
activation. 
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TABLE 11 







Percentage of total 
iodine Micrograms total 
iodine 
per Curie u'l tri 1291 1311 
1 8 0.1 22 78 10 
10 8 3.0 34 63 13 
20 8 5.0 42 53 15 
40 8 8.0 55 37 22 
32 I 0.4 68 31 26 
10 32 7.0 76 17 47 
20 32 10.0 78 12 66 
40 32 12.0 81 7 116 
° Calculated relative amounts of fission product iodine isotopes present 8 and 32 
days after bombardment of 23'U in iodine separated immediately after activation. 
fission-produced 131 1 might again become available, or the production of 
131 1 from tellurium highly enriched in 130Te become economically feasible. 
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Background 
The use of radiolabeled peptides and proteins as tracers in radioimmu-
noassay (MA), receptor binding, biosynthesis, and microsequencing 
studies has gained wide acceptance owing to .the ease of preparation. the 
high specific activities obtainable, and the sensitivity of detection. High-
performance liquid chromatography (HPLC) has been used to purify and 
characterize radiolabeled polypeptides as an efficient and rapid alterna- 
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